Navigation Links
ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
Date:12/15/2011

YOKOHAMA, Japan, December 15, 2011 /PRNewswire/ --

ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company licensed worldwide right to commercialize hepatocytes derived from human iPS (induced pluripotent stem) cells. ReproCELL has been collaborating with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan) to establish an effective in-vitro drug screening for hepatic toxicity and liver metabolism using hepatocytes derived from human iPS cells since early this year.

Together with NIBIO, the company successfully established the hepatocytes which highly express active drug metabolizing enzyme. Currently, the company is evaluating the system using various drugs with pharmaceutical companies to observe how the drugs are metabolized.  ReproCELL is anticipating its commercialization in Q2 2012. Prior to the launch, sample of the cells will become available for testing to pharmaceutical and biotech companies in January 2012.

ReproCELL is a world-leading pioneer in commercializing human pluripotent stem cells as an effective tool for drug discovery and development. The company has successfully launched iPS cell derived cardiomyocytes in April 2009 for cardiac toxicity testing, followed by the launch of iPS cell derived neuronal cells in October 2010 for efficacy screening of neuroactive compounds.

ReproCELL's Representative Director and CEO, Chikafumi Yokoyama PhD commented, "We are pleased to see iPS cell-derived hepatocytes showing the highest level of quality ever seen, expressing the same qualities as that of primary human hepatocytes currently used by the pharmaceutical industry, including drug metabolizing enzyme activity. We can expect to see its early adoption for drug toxicity and pharmacokinetic studies."

Aspects of NIBIO's technology on the induction of iPS cell-derived hepatocyte differentiation can be found in the following publication:

Efficient Generation of Functional Hepatocytes From Human Embryonic Stem Cells and Induced Pluripotent Stem Cells by HNF4α Transduction.

Takayama K, Inamura M, Kawabata K, Katayama K, Higuchi M, Tashiro K, Nonaka A, Sakurai F, Hayakawa T, Kusuda Furue M, Mizuguchi H., Mol Ther. 2011 Nov 8. [Epub ahead of print] PMID: 22068426

Company:  ReproCELL Inc.
Representative: Chikafumi Yokoyama PhD,
Contact:  info_repro@reprocell.com   Tel:+81-(0)45-475-3887
KDX Shin-Yokohama 381 bldg. 8F, 3-8-11 Shin-Yokohama, Kohoku-ku,
Yokohama, Kanagawa 222-0033, Japan



'/>"/>
SOURCE ReproCELL Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells
2. SK Life Sciences has Licensed Pristima
3. NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
4. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
5. Full Agenda Announced for CMAC 2011 - CBIS 2nd Annual Commercialization and Market Access Congress
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium
8. Saladax Biomedical, Inc. Announces European Commercialization Team
9. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)
10. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
11. Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 22, 2017   Boston Biomedical , an industry ... to target cancer stemness pathways, today announced its Board ... as Chief Executive Officer, effective April 24, 2017. ... Li , M.D., FACP, who has led Boston Biomedical ... his leadership, Boston Biomedical has grown from a "garage ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... ... of biologics. To acquire information on the desired increase and/or decrease in antibody-dependent ... industry for rapid N-glycosylation profiling of therapeutic antibodies. , To meet this ...
(Date:3/22/2017)... (PRWEB) , ... March 21, ... ... ( WMFTG ) has unveiled its innovative Quantum peristaltic pump with patented ... innovation, Quantum sets the new standard for high-pressure feed pumps in SU ...
(Date:3/22/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... Lebovits , Chief Executive Officer, will provide an update ... Associates 2 nd Annual Neuroscience Biopartnering and Investment ... the New York Academy of Sciences. ...
Breaking Biology Technology:
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):